Treatment with human wharton’s jelly-derived mesenchymal stem cells attenuates sepsis-induced kidney injury, liver injury, and endothelial dysfunction

Stem Cells Translational Medicine

Volumn 5, Issue 8, 2016, Pages 1048-1057

  Cóndor, José M ^a,b   Rodrigues, Camila E ^a   Sousa Moreira, Roberto De ^a   Canale, Daniele ^a   Volpini, Rildo A ^a   Shimizu, Maria H M ^a   Camara, Niels O S ^a   Noronha, Irene De L ^a   Andrade, Lúcia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD NACIONAL MAYOR DE SAN MARCOS   (Peru)

Author keywords

Apoptosis; Endothelium derived factors; Interleukins; Kidney injury; Liver injury; Wharton s jelly derived mesenchymal stem cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; KLOTHO PROTEIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BETA GLUCURONIDASE;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; CHONDROGENESIS; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FLOW CYTOMETRY; GLOMERULUS FILTRATION RATE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFLAMMATION; KIDNEY INJURY; LIVER INJURY; MALE; MESENCHYMAL STROMA CELL; MORPHOMETRICS; NONHUMAN; OSMOLALITY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RAT; SEPSIS; ACUTE KIDNEY INJURY; ANIMAL; CELL CULTURE; CYTOLOGY; DISEASE MODEL; KIDNEY; LIVER; LIVER DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHENOTYPE; TIME FACTOR; VASCULAR ENDOTHELIUM; WHARTON JELLY; WISTAR RAT;

ACUTE KIDNEY INJURY; ANIMALS; APOPTOSIS; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GLOMERULAR FILTRATION RATE; GLUCURONIDASE; HUMANS; INFLAMMATION MEDIATORS; KIDNEY; LIVER; LIVER DISEASES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NF-KAPPA B; PHENOTYPE; RATS, WISTAR; SEPSIS; TIME FACTORS; WHARTON JELLY;

EID: 84978664385     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0138     Document Type: Article

References (40)

1. Jawad I, Lukšić I, Rafnsson SB. Assessing available information on the burden of sepsis: Global estimates of incidence, prevalence and mortality. J Glob Health 2012;2:010404.
2. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580–637.
3. Abraham E, Singer M. Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 2007;35:2408–2416.
4. Bagshaw SM, Uchino S, Bellomo R et al. Septic acute kidney injury in critically ill patients: Clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007;2:431–439.
5. Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited: Pathophysiology, prevention and future therapies. Curr Opin Crit Care 2014;20:588–595.
6. Ye X, Ding J, Zhou X et al. Divergent roles of endothelial NF-kappaB in multiple organ injury and bacterial clearance in mouse models of sepsis. J Exp Med 2008;205:1303–1315.
7. O’Sullivan AW, Wang JH, Redmond HP. NF-kappaB and p38 MAPK inhibition improve survival in endotoxin shock and in a cecal ligation and puncture model of sepsis in combination with antibiotic therapy. J Surg Res 2009;152: 46–53.
8. López A, Lorente JA, Steingrub J et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32: 21–30.
9. Qin S, Wang H, Yuan R et al. Role ofHMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006;203:1637–1642.
10. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008;8:776–787.
11. Kotsaki A, Giamarellos-Bourboulis EJ. Emerging drugs for the treatment of sepsis. Expert Opin Emerg Drugs 2012;17:379–391.
12. Xu J, Woods CR, Mora AL et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 2007; 293:L131–L141.
13. Elman JS, Li M, Wang F et al. A comparison of adipose and bone marrow-derived mesenchymal stromal cell secreted factors in the treatment of systemic inflammation. J Inflamm (Lond) 2014;11:1.
14. Jin HJ, Bae YK, Kim M et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci 2013;14:17986–18001.
15. Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate MSC-like cells from umbilical cord. STEM CELLS 2003;21:105–110.
16. Watson N, Divers R, Kedar R et al. Discarded Wharton jelly of the human umbilical cord: A viable source for mesenchymal stromal cells. Cytotherapy 2015;17:18–24.
17. Hu MC, Shi M, Zhang J et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and itsreplacement isprotective. Kidney Int 2010;78:1240–1251.
18. Jorge L, Coelho F, Sanches TR et al. Klotho deficiency aggravates sepsis-related multiple organ dysfunction [Abstract]. J Am Soc Nephrol 2013;24: 85.
19. Zeldich E, Chen CD, Colvin TA et al. The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. J Biol Chem 2014;289:24700–24715.
20. Oh HJ, Nam BY, Lee MJ et al. Decreased circulating klotho levels in patients undergoing dialysis and relationship to oxidative stress and inflammation. Perit Dial Int 2015; 35:43–51.
21. Yang HC, Rossini M, Ma LJ et al. Cells derived from young bone marrow alleviate renal aging. J Am Soc Nephrol 2011;22:2028–2036.
22. Maekawa Y, Ishikawa K, Yasuda O et al. Klotho suppressesTNF-alpha-inducedexpression of adhesion moleculesin theendothelium andat-tenuates NF-kappaB activation. Endocrine 2009; 35:341–346.
23. Mei SH, Haitsma JJ, Dos Santos CC et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010;182:1047–1057.
24. Chang CL, Leu S, Sung HC et al. Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in rat sepsis syndrome induced by cecal puncture and ligation. J Transl Med 2012;10:244.
25. Doi K, Leelahavanichkul A, Yuen PS et al. Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest 2009;119:2868–2878.
26. Rodrigues CE, Sanches TR, Volpini RA et al. Effects of continuous erythropoietin receptor activator in sepsis-induced acute kidney injury and multi-organ dysfunction. PLoS One 2012;7:e29893.
27. Souza AC, Volpini RA, Shimizu MH et al. Erythropoietin prevents sepsis-related acute kidney injury in rats by inhibiting NF-kB and upregulating endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2012;302: F1045–F1054.
28. Yagi H, Soto-Gutierrez A, Kitagawa Y et al. Bone marrow mesenchymal stromal cells attenuate organ injury induced by LPS and burn. Cell Transplant 2010;19:823–830.
29. Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006;290:L622–L645.
30. Leelahavanichkul A, Yasuda H, Doi K et al. Methyl-2-acetamidoacrylate, an ethyl pyruvate analog, decreases sepsis-induced acute kidney injury in mice. Am J Physiol Renal Physiol 2008;295:F1825–F1835.
31. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006;6:813–822.
32. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815–1822.
33. English K, Ryan JM, Tobin L et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156:149–160.
34. Di Ianni M, Del Papa B, De Ioanni M et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008;36:309–318.
35. Kusadasi N, Groeneveld AB. A perspective on mesenchymal stromal cell transplantation in the treatment of sepsis. Shock 2013; 40:352–357.
36. Kyurkchiev D, Bochev I, Ivanova-Todorova E et al. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells 2014;6:552–570.
37. Jesmin S, Zaedi S, Islam AM et al. Time-dependent alterations of VEGF and its signaling molecules in acute lung injury in a rat model of sepsis. Inflammation 2012;35:484–500.
38. Xu C, Chang A, Hack BK et al. TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis. Kidney Int 2014;85:72–81.
39. Rochefort GY, Delorme B, Lopez A et al. Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. STEM CELLS 2006;24:2202–2208.
40. Gonzalez-Rey E, Anderson P, González MA et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009;58:929–939.